Sign In
Buy CDXS
$1.40
-0.0800 (-5.41%)
At Close: Jul 31, 2026
Codexis Is Chasing a Blockbuster Opportunity. Can It Compete With Gene Therapies?
03:58pm, Tuesday, 28'th Jan 2020
The company is developing a novel enzyme-based treatment for phenylketonuria (PKU), but it faces growing competition from potentially curative gene therapies.
Codexis (NASDAQ:CDXS) Downgraded by Zacks Investment Research to "Hold"
10:40am, Monday, 27'th Jan 2020
Zacks Investment Research lowered shares of Codexis (NASDAQ:CDXS) from a buy rating to a hold rating in a report released on Friday, Zacks.com reports. According to Zacks, “Codexis is a leading prot
Codexis (NASDAQ:CDXS) Raised to Buy at Zacks Investment Research
11:18am, Sunday, 26'th Jan 2020
Zacks Investment Research upgraded shares of Codexis (NASDAQ:CDXS) from a hold rating to a buy rating in a research report report published on Wednesday morning, Zacks.com reports. They currently have
Codexis (NASDAQ:CDXS) Stock Rating Lowered by BidaskClub
09:56am, Sunday, 26'th Jan 2020
BidaskClub lowered shares of Codexis (NASDAQ:CDXS) from a buy rating to a hold rating in a research report report published on Wednesday morning, BidAskClub reports. A number of other research firms h
Exchange Traded Concepts LLC Takes Position in Codexis, Inc. (NASDAQ:CDXS)
10:12am, Saturday, 25'th Jan 2020
Exchange Traded Concepts LLC acquired a new stake in shares of Codexis, Inc. (NASDAQ:CDXS) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 4,045 shares of the biotechnology comp
Codexis, Inc. (NASDAQ:CDXS) Director Bernard J. Kelley Sells 2,500 Shares
11:32am, Thursday, 23'rd Jan 2020
Codexis, Inc. (NASDAQ:CDXS) Director Bernard J. Kelley sold 2,500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $18.00, for
Insider Selling: Codexis, Inc. (NASDAQ:CDXS) Director Sells $186,800.00 in Stock
09:58am, Monday, 20'th Jan 2020
Codexis, Inc. (NASDAQ:CDXS) Director Thomas R. Baruch sold 10,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $18.68, for a total tr
Here’s Why We’re Not Too Worried About Codexis’s (NASDAQ:CDXS) Cash Burn Situation
01:09pm, Sunday, 19'th Jan 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Codexis (NASDAQ:CDXS) Upgraded by BidaskClub to Buy
07:24am, Wednesday, 15'th Jan 2020
Codexis (NASDAQ:CDXS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports. Several other bro
Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing
09:05pm, Monday, 13'th Jan 2020
Codexis, Inc. (CDXS) today announced that it has attended the official opening of Porton Pharma Solutions Ltd.’s (300363.SZ) fermentation pilot laboratory located in Porton’s Changshou site, achie
Codexis Attends Opening Ceremony for Porton’s Fermentation Pilot Lab in Chongqing
09:05pm, Monday, 13'th Jan 2020
CHONGQING, China, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) today announced that it has attended the official opening of Porton...
BRIEF-Codexis And Nestl Health Science Sign Development Deal
12:27pm, Friday, 10'th Jan 2020
Codexis Inc:
Codexis, Inc. (CDXS), a leading protein engineering company and developer of novel biotherapeutics, and Nestlé Health Science, a globally recognized leader in the field of nutritional science, have s
REDWOOD CITY, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company and developer of novel...
